Our name, 2seventy bioTM, is inspired by the maximum speed of translating human thought into action — 270 miles per hour. At 2seventy bio, we think in the language of time. It’s about timeTM we endeavor to outmaneuver cancer so the people we serve can have the chance for MORE…more time building stories with families and friends, experiencing their passions, and living their best lives in the big and small moments. Too many have lost time to cancer, and we are wildly impatient to help change that.
At 2seventy bio, we have the benefit of time and experience that we apply to our mission. We carry with us a legacy of deep care for patients and our people, thought leadership, learnings, and scientific expertise from our gene therapy and oncology roots.
Each of us has been impacted by cancer - a family member, a friend, a colleague. We start from a very human place, knowing that the most important thing we can do is deliver more time... to people living with multiple myeloma. It is this mindset and approach that will propel us forward because we know that time matters — every day, every minute, every second — to people living with multiple myeloma.
At 2seventy bio, we believe that it’s about time that Diversity, Equity, Inclusion and Belonging become more than words. It is the core practice we are driven by in all we create. From our focus on patients, to how we are building our business and our culture, we believe diversity and belonging empower us to change the way we think, teach, and learn — from each other and about each other. Our mission is rooted in the belief that our cumulative and unique differences enable us to become better — better at our development of revolutionary scientific advancements and how we advance health equity by addressing cancer disparities with a goal of creating transformative treatments for those who need them. We strive to build an environment where we will deliver our best — that means having the hard conversations and doing the hard work — so we can all be unencumbered and inspired to celebrate who we are fully as human beings.
Since entering into an agreement in 2013, 2seventy bio and Bristol Myers Squibb (BMS) have been collaborating to develop CAR T cell therapies targeting B cell maturation antigen (BCMA). ABECMA® (idecabtagene vicleucel) is being jointly developed and commercialized in the United States as part of a Co-Development, Co-Promotion, and Profit Share Agreement with BMS and 2seventy bio. BMS continues to have sole responsibility for drug product manufacturing and commercialization outside the United States.
At 2seventy bio, we carry with us a legacy of deep care for patients, our people, and doing what is right by them. We ensure transparency in all areas of our business, conduct ourselves at all times as outlined in our Code of Business Conduct and Ethics, and hold ourselves accountable to meet expectations as a partner in this field – because we know we can’t do this alone.